PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Projects Exponential Growth for European Personalised Medicine Market - Stating that current levels of double-digit growth are only the tip of the iceberg, Frost & Sullivan projects exponential growth for the European personalised medicine market
Frost & Sullivan Projects Exponential Growth for European Personalised Medicine Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/04/04 - Stating that current levels of double-digit growth are only the tip of the iceberg, Frost & Sullivan projects exponential growth for the European personalised medicine market.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Defining the scope and nature of human biological variation allows the targeting of medical treatments towards those most likely to benefit from it. Such treatments may include drugs or cell therapies customised to a patient's history, genes and immunology. In essence, the phenomenon of each human being unique creates immense opportunities for personalised medicine.

New analysis from Frost & Sullivan (pharma.frost.com), Personalised Medicine in Europe, finds that the European personalised medicine market is currently growing at double digit growth rates, which is significant especially as it comes from an already high base. This growth rate is poised to increase as more European governments promote personalised healthcare, aiding its mainstream implementation.

"The most important benefit of personalised medicine is that it improves the design, power and predictability of a clinical trial, which will then further aid in getting better outcomes in lesser time," notes Frost & Sullivan Senior Research Analyst Rasika Ramachandran. "Personalised medicine helps reduce subject recruiting time in clinical trials, improves drug response, and minimises adverse reactions.

It also reduces misdiagnoses. Personalised medicine enables faster diagnosis when applied as a companion diagnostic test along with a drug, thereby also aiding in developing better differentiated drug products.

The role of physicians is very critical in the promotion of companion diagnostic tests. These tests restrict a physician from prescribing a drug of his choice.

"Often, they doubt the ability of a companion test to prescribe the drug compared to their knowledge and experience," explains Ramachandran. "Therefore, removing this stigma and encouraging a new generation of physicians with a positive attitude towards theranostics will help to overcome this challenge."

The technical efficacy of theranostics, coupled with the lowering of associated research and development (R&D) costs, will be key drivers in sustaining growth momentum in the market. However, pharmaceutical companies and diagnostic firms need to collaborate more closely with physicians during the theranostic development process, so that when the test is on the market, the endorsement of fellow physicians will aid in its greater adoption.

Promisingly, a number of public-private partnerships and high levels of technological advancements, which support the discovery and development of new biomarkers will also spur market prospects.

A key challenge remains reimbursement. This issue prevents physicians from prescribing companion diagnostic tests, as they are mostly out-of-pocket or only partly reimbursed.

"Unless reimbursement issues are sorted out or these tests become affordable enough for full out of pocket payment, the companion diagnostic companies face a dead stand off," cautions Ramachandran. "European governments are taking initiatives to solve these issues, which acts as a positive sign for personalised medicine companies."

If you are interested in more information about this study, please send an email with your contact details to Chiara Carella, Corporate Communications, at chiara.carella[.]frost.com.

Personalised Medicine in Europe is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Tissue Diagnostics Markets and European Diabetes Diagnostics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Personalised Medicine in Europe / M668

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Projects Exponential Growth for European Personalised Medicine Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Chiara Carella 
+44 (0) 20 7343 8314 chiara.carella[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)